Author: Healthcare Propulsion Staff

At least 16 elderly residents have died in a fire at a nursing home in Chile, according to authorities.Ten others were evacuated after a blaze broke out at El Edén home in /idt2/d9cfcc9a-2842-463f-a4d8-4dd007ef9547, around 640km (400 miles) south of the capital Santiago, on Friday evening. Jorge Granada, a prosecutor leading the case, said it was not clear at this stage what caused the incident.Chile’s President José Antonio Kast said he had ordered a review into the condition of nursing homes across the country.”We will fully collaborate with the justice system to clarify what happened, determine where failures may have existed…

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC). Pumitamig is an investigational PD-L1 x VEGF-A bispecific antibody, while elfe-D is an investigational B7H3 antibody-drug conjugate. The study represents the first reported data evaluating a PD-(L)1 x VEGF bispecific antibody combined with an antibody-drug conjugate in lung cancer. “The early activity…

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study. These results will be presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea. Results from the randomized dose-expansion cohort of the global Phase 1 study showed increasing clinical activity with higher dose levels. At the recommended Phase 3 dose of 2.5 mg/kg,…

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial. These results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea. The study also demonstrated substantially higher pathological response rates with the atezolizumab regimen. Pathological complete response rates reached 29.6% versus 8.5%, while major pathological response rates were 53.6%…

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC). Local consolidative therapy has improved outcomes in selected patients with oligometastatic NSCLC treated with chemotherapy, but its role in patients receiving immune checkpoint inhibitors has remained uncertain. The Phase III LONESTAR trial tested whether reducing residual tumor burden with radiation or surgery after dual…

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC). Tarlatamab administered at 10 mg every two weeks has previously demonstrated superior overall survival compared with chemotherapy in patients with previously treated SCLC. DeLLphi-309 evaluated whether less frequent dosing of 20 mg every three weeks or 30 mg every four weeks could…

Scientists melted diamonds with a powerful laser to take some of the most precise measurements of the mineral’s elusive melting point — and found that previous experiments were off by more than 1,300 degrees Fahrenheit (700 degrees Celsius).It’s odd to think of diamond, the hardest natural material on Earth, melting — but melt it does when blasted with extremely powerful lasers under the right conditions. Understanding how diamond responds to shock waves from lasers is an important part of developing nuclear fusion, the process that powers stars. Nuclear fusion is also a potential energy source for the future, so researchers…

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC). Tarlatamab is a bispecific T-cell engager (BiTE®) immunotherapy with established clinical activity in small cell lung cancer and has previously been evaluated using intravenous administration. DeLLphi-308 is the first study to investigate subcutaneous delivery, an approach that may improve convenience and produce delayed lower peak serum concentrations than intravenous…

Artificial intelligence (AI) algorithms that hunt for cancer may do a better job when they approach the analysis as if they were a human pathologist, a new study suggests.Many AI systems analyze preselected regions of a tissue sample, or they split a whole pathology slide into patches of a fixed size. By contrast, a pathologist searches more dynamically, panning across the tissue, zooming in and out, and pausing over areas that raise red flags. A whole slide can contain billions of pixels, while the evidence of cancer may occupy only a tiny patch.Study co-author Zhi Huang, an assistant professor of…

The Celestron StarSense Explorer DX 130AZ is a 5.1-inch (130mm) f/5 Newtonian reflector, one of many 130mm f/5 reflectors offered by Celestron. The DX 130AZ is also one of two 130mm StarSense Explorer variants, the other being a tabletop Dobsonian. The optical tube here rides on an alt-azimuth tripod instead and uses a 2-inch focuser, but otherwise, there are no major differences.The DX 130 AZ is certainly one of the better telescopes in the StarSense Explorer series; there are also several decent Dobsonians, a pair of decent Schmidt-Cassegrains, the merely acceptable DX 102 refractor, a 114mm Bird-Jones model and some…